.png)
A game changer in neurodegeneration, healthy ageing and longevity.
Neuroplast is advancing Neuro-Cells®, an autologous bone marrow-derived stem cell therapy harnessing the body’s own regenerative capacity to treat neurological disease.
Building on encouraging Phase II clinical data, Neuroplast is advancing Neuro-Cells® in spinal cord injury (SCI).
Promising preclinical data combined with existing safety data are driving pipeline expansion into Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and healthy CNS ageing.
ABOUT US
Inspired by nature. Using your own cell regeneration toolbox.
Made to reverse neurodegeneration. Made to improve lives.
Founded in Maastricht in 2017, Neuroplast develops regenerative therapies harnessing the body’s innate healing capacity. Its proprietary Neuro-Cells® product is an autologous bone marrow-derived stem cell therapy that preserves the regenerative potential of a patient’s own cells in its native form.
Neuroplast has completed Phase I and II trials in spinal cord injury (SCI), demonstrating a safe profile and clinical efficacy.
Neuroplast is advancing Neuro-Cells® in SCI, Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) and healthy ageing, supported by Phase II clinical data and more than 21 peer-reviewed publications.
Our Mission
Develop safe and effective stem cell therapies that restore function and improve lives.
Our Vision
A world where neurodegenerative diseases are treatable and healthy ageing is achievable for all.
SCIENCE
Untouched cells transforming the treatment of neurological disorders
Patient Autologous
Using the patient's own cells – untouched unchanged
Maximum Cell Integrity
Cells preserved in the state nature perfected for regeneration
Rapid, Not Expanded.
Manufactured in hours, not weeks
Clinically Validated
Phase II data with meaningful outcomes and strong safety profile
GMP Manufacturing
Manufactured under the highest regulatory standards
Clean, Effective, Focused
Cell therapy without genetic modification or off-tar
A different approach.
A different product.
A better future.
-
Is an autologous bone marrow-derived stem cell mixture, preserving the cells' natural adaptability without ex vivo modification.
-
Restores CNS homeostasis disrupted by neurodegeneration.
-
Favorable safety profile: autologous therapy with no graft-versus-host disease, no tumorigenicity observed,
-
Safety demonstrated in Phase I and II clinical SCI studies traumatic spinal cord injury.
Preserving nature’s adaptive cellular regeneration toolbox
Native cells. Smarter inflammation control.
Neuro-Cells® modulates harmful inflammatory responses, helping restore local homeostasis.
Inflammation Control
Replenish. Repair. Reconnect.
Neuro-Cells® supports resident cells, promotes tissue restoration, and helps rebuild damaged neural networks.
Regeneration & Repair
Restore balance. Enable repair.
Paracrine signaling creates a regenerative environment by reducing scarring and factors that inhibit axonal growth and reconnection.
Restore Homeostasis
Cells communicate. Repair begins.
Cell-to-cell signaling coordinates the local response, enabling the tissue’s intrinsic regenerative processes.
Paracrine Modulation
CLINICAL EVIDENCE
Phase II. Real data. Real impact.
Randomised, double-blinded Phase II trial in subacute spinal cord injury confirmed safety, showed meaningful and durable improvements in motor and sensory function, and significantly:
-
improved neurogenic bowel function,
-
reduced neuropathic pain,
-
improved Quality of Life Score.
Improved neurogenic bowel function
Reduced neuropathic pain
Improved Quality of Life
Statistically significant improvement of bowel function. All early treated patients were continent.
Statistically significant reduction of neuropathic pain. No long-term use of opioids required.
Creates a therapeutic opportunity where no approved treatment provides meaningful, durable relief.
Bowel control and chronic pain relief belong to the top 6 QoL impacting factors. Recovery of bowel function is top-3 priority, pain is top-6 priority. Neuro-Cells® treatment has the potential to improve these functions.
Mode of Action: The Mixed Cell Population Secretome
-
Native stem and precursor cells secrete a cocktail of bioactive molecules called paracrine secretome, which influence nearby cells.
-
Efficacy from stem cells could be broader than may be expected from single compound modulating single biological target.
Infographic based on Nguyen et al (2023) Cell Mol Neurobiol 43, 3211–3250
Mode of Action: Counteracting the Inflammasome
Figure taken from: biospective.com/resources/what-is-interleukin-1-beta
-
Neuro-Cells® reduces neuroinflammation by reducing serum cytokine levels in SCI patients and in animal models of SCI, ALS, AD.
-
Consistent with inhibition of inflammasome in microglia.
-
Neuro-Cells® also improved other hallmarks of neurodegeneration in animal models:
-
Preservation of neurons through reduced cell death
-
Prevention of formation of new amyloid plaques
-
Reduction of GSK-3β levels, could reduce twisted Tau fibers
-
PIPELINE
Transforming potential into life-changing therapies.
Spinal Cord Injury (SCI)
Phase II clinical evidence in spinal cord injury
Neuro-Cells® demonstrated a favorable safety profile and significant neurological and functional impro
vements in a Phase II SCI trial, and improvements in neurogenic bowel dysfunction and neuropathic pain. Clinical and preclinical findings support a strong anti-inflammatory and neuroprotective effect, with reductions in serum levels of IL-6, TNF-α and IL-1β. In a preclinical SCI model, Neuro-Cells® reduced neuroinflammation and spinal cord cell death and outperformed methylprednisolone. Orphan Drug Designation (ODD) granted.
Confirmatory Program under conditional marketing authorization
Alzheimer's Disease (AD)
Promising preclinical evidence in Alzheimer’s disease
In a preclinical AD model, Neuro-Cells® significantly preserved cognitive function and reduced amyloid plaque formation. Neuro-Cells® targeted key drivers of neuroinflammation and neurodegeneration, significantly reducing IL-6, TNF-α and IL-1β in the brain and limiting amyloid plaque and tau pathology.
Objective Phase 1b/2a trial
Amyotrophic Lateral Sclerosis (ALS)
Promising preclinical evidence in ALS
Neuro-Cells® aims to slow ALS disease progression by preserving motor neuron and muscle function.
In a preclinical ALS model, Neuro-Cells® preserved limb function, protected motor neurons and muscle tissue, and reduced neuroinflammation—outperforming riluzole.
Objective Phase 1b/2a trial
Longevity & Healthy Ageing
Promising potential for CNS longevity
Across preclinical models and clinical trial, Neuro-Cells® preserved neurological function, protected neurons and reduced neuroinflammation—key biological processes associated with maintaining CNS resilience and function during ageing.
These findings support exploring Neuro-Cells® as an approach promoting healthy CNS ageing and extend neurological healthspan.
Future Program
Advancing Neuro-Cells® from Evidence to Access.
Intellectual Property
More than 5 new patent applications are under development. These new applications will protect various innovative aspects of the composition, selection, and manufacturing of Neuro-Cells®.
NEUROPLAST TEAM
Frans van de Berg MSc, MBA
Chief Executive Officer
General Management, Strategy, Finance, HR, Legal, BD&L
Fund raising: >2B USD in total deal value
~30 yrs of leadership experience across biotech, medtech, big pharma and VC
Johannes de Munter MD, PhD
Founder, Chief Medical Officer
Co-inventor and Developer of Neuro-Cells®, Certified Scenario Epidemiologist, Physician with comprehensive experience in CNS, ~20 yrs experience leading organizations in stem-cell applications
Arthur Oubrie PhD
Chief Scientific Officer
Drug hunter across indications and modalities, co-inventor of the blockbuster medicine Calquence®
~25 yrs experience leading R&D teams in biotech, pharma, Academia
Ekkehard Lang PhD
Chief Operating Officer
Co-inventor and Developer Neuro-Cells®, CMC specialist, Qualified Person for ATMPs,
>25 yrs experience leading teams developing (stem)cell applications across organizations
SCIENTIFIC ADVISORY BOARD
NEWS
SEP 15, 2026 — Neuroplast Phase II Clinical Results in Spinal Cord Injury published in BMC Medical
JUN 30, 2026 — Neuroplast Appoints New Chief Executive Officer F. van den Berg
JUN 30, 2026 — Neuroplast Appoints New Chief Scientific Officer A. Oubrie
APR 24, 2026 — Neuroplast Strengthens Scientific Advisory Board
AUG 18, 2025 — New Publication Highlights Neuro-Cells® Therapeutic Potential Therapeutic Effects of Neuro-Cells on Amyloid Pathology, BDNF Levels, and Insulin Signalling in APPswe/PSd1E9 Mice, Cells 2025, 14(16), 1293; https://doi.org/10.3390/cells14161293
JUL 29, 2025 — New Publication Highlights Neuro-Cells® Therapeutic Potential in AD, Neuro-Cells Mitigate Amyloid Plaque Formation and Behavioral Deficits in the APPswe/PS1dE9 Model of Alzheimer Disease While Also Reducing IL-6 Production in Human Monocytes
Cells 2025, 14(15), 1168; https://doi.org/10.3390/cells14151168
CONTACT US
We welcome discussions
Neuroplast is exploring partnerships to advance its autologous cell therapy platform across CNS indications and future applications. We welcome discussions with pharma, biotech, healthcare providers, and research organisations interested in leveraging a scalable platform with broad therapeutic potential. Please contact info@neuroplast.com.
Call
+31 (0) 85 - 076 1000
Corporate Location
Neuroplast B.V., Sleperweg 36 6222 NK Maastricht, Netherlands